Key clinical point: Longer-term results from IMMhance study showed patients treated with risankizumab experienced skin clearance.

Major finding: After 94 weeks, 73% and 72% of patients treated with continuous risankizumab experienced complete skin clearance, among patients who achieved sPGA 0/1 at week 28.

Study details: IMMhance is an ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of risankizumab compared to placebo in adult patients with moderate to severe plaque psoriasis.